Literature DB >> 33846105

Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy.

Christopher N Fortner1, Julie M Seguin2, Denise M Kay3.   

Abstract

Entities:  

Keywords:  CFTR modulator; Elexacaftor; Fecal elastase; Immunoreactive trypsinogen; In utero exposure; Ivacaftor; Newborn screen; Pancreatic dysfunction; Pregnancy; Tezacaftor

Mesh：

Substances：

Year:  2021        PMID： 33846105     DOI： 10.1016/j.jcf.2021.03.018

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN： 1569-1993            Impact factor:   5.482


× No keyword cloud information.
  9 in total

Review 1.  Increasing life expectancy in cystic fibrosis: Advances and challenges.

Authors:  Kimberly A McBennett; Pamela B Davis; Michael W Konstan
Journal:  Pediatr Pulmonol       Date:  2021-11-11

2.  Current clinical opinion on CFTR dysfunction and patient risk of pancreatitis: diagnostic and therapeutic considerations.

Authors:  Madhura Y Phadke; Zachary M Sellers
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2022-06-02       Impact factor: 4.095

3.  Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design.

Authors:  Raksha Jain; Amalia Magaret; Phuong T Vu; Jill M VanDalfsen; Ashley Keller; Alexandra Wilson; Melissa S Putman; Nicole Mayer-Hamblett; Charles R Esther; Jennifer L Taylor-Cousar
Journal:  BMJ Open Respir Res       Date:  2022-06

Review 4.  Family-building and parenting considerations for people with cystic fibrosis.

Authors:  Traci M Kazmerski; Natalie E West; Raksha Jain; Ahmet Uluer; Anna M Georgiopoulos; Moira L Aitken; Jennifer L Taylor-Cousar
Journal:  Pediatr Pulmonol       Date:  2021-08-18

Review 5.  The Exocrine Pancreas in Cystic Fibrosis in the Era of CFTR Modulation: A Mini Review.

Authors:  Isabelle R McKay; Chee Y Ooi
Journal:  Front Pediatr       Date:  2022-06-27       Impact factor: 3.569

6.  Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score.

Authors:  Jochen G Mainz; Carlos Zagoya; Louise Polte; Lutz Naehrlich; Lenny Sasse; Olaf Eickmeier; Christina Smaczny; Anton Barucha; Lilith Bechinger; Franziska Duckstein; Ludwik Kurzidim; Patience Eschenhagen; Laura Caley; Daniel Peckham; Carsten Schwarz
Journal:  Front Pharmacol       Date:  2022-06-03       Impact factor: 5.988

7.  Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor.

Authors:  Bethany Collins; Christopher Fortner; Amanda Cotey; Charles R Jr Esther; Aaron Trimble
Journal:  J Cyst Fibros       Date:  2021-12-22       Impact factor: 5.527

Review 8.  Going the Extra Mile: Why Clinical Research in Cystic Fibrosis Must Include Children.

Authors:  Rebecca Dobra; Siân Bentley; Claire Edmondson; Maxine Ovens; Clare Saunders; Christopher Short; Gemma Wilson; Jane C Davies; Andrew Bush
Journal:  Children (Basel)       Date:  2022-07-20

Review 9.  Fertility, Pregnancy and Lactation Considerations for Women with CF in the CFTR Modulator Era.

Authors:  Raksha Jain; Jennifer L Taylor-Cousar
Journal:  J Pers Med       Date:  2021-05-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.